Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | ESRRG | P62508 | 2/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | ESRRB | O95718 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | CTSG | P08311 | 1/20 | 0.43 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL507205 | 0.88 | ADORA2A (0.50) | NAMPTMEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL20300612 | 0.84 | CYP1A2 (0.47) | MEN1CYP1A2CYP2C19KMT2ACA1 | |
| SCHEMBL12301890 | 0.81 | NPC1 (0.57) | NAMPTKMT2AHDAC6LMNARAB9A | |
| SCHEMBL20788451 | 0.79 | OGG1 (0.53) | NAMPTMEN1KMT2AHDAC6HDAC3 | |
| SCHEMBL6078477 | 0.79 | MEN1 (0.56) | MEN1CYP1A2CYP2C19KMT2ACA1 | |
| SCHEMBL21590340 | 0.79 | PRSS1 (0.65) | NAMPTKMT2AEPHX2HDAC6ESRRG | |
| SCHEMBL21674205 | 0.78 | CA1 (0.55) | MEN1CYP1A2CYP2C19KMT2ACA1 | |
| SCHEMBL507514 | 0.77 | CA1 (0.50) | MEN1CYP1A2CYP2C19KMT2ACA1 | |
| SCHEMBL7891123 | 0.77 | DGAT1 (0.47) | NAMPTMEN1KMT2ACA1CA2 | |
| SCHEMBL20804023 | 0.77 | RAB9A (0.55) | NAMPTMEN1KMT2ALMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2022-08-16 | — | — | US | disclosed |
| US-20200231567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2020-07-23 | — | — | US | disclosed |
| US-10669257-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| EP-3599236-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2020-01-29 | — | — | EP | disclosed |
| EP-3202460-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20190135780-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2019-05-09 | — | — | US | disclosed |
| EP-3106460-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-2536706-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-3106460-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160159772-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-20160159768-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-9309219-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2016-04-12 | — | — | US | disclosed |
| US-20130324518-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2013-12-05 | — | — | US | disclosed |
| US-8518972-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2536706-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011100380-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324518-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | NAMPT 403/4885MEN1 3301/4885CYP1A2 13/4885 |
| US-20160159768-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | NAMPT 403/4885MEN1 3301/4885CYP1A2 13/4885 |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CYP3A7, CYP3A4, CYP3A43 | NAMPT 403/4885MEN1 3301/4885CYP1A2 13/4885 |
| US-10669257-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CYP3A7, CYP3A4, CYP3A43 | NAMPT 403/4885MEN1 3301/4885CYP1A2 13/4885 |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | NAMPT 403/4885MEN1 3301/4885CYP1A2 13/4885 |
| US-20200231567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | NAMPT 403/4885MEN1 3301/4885CYP1A2 13/4885 |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CYP3A7, CYP3A4, CYP3A43 | NAMPT 403/4885MEN1 3301/4885CYP1A2 13/4885 |
| US-20190135780-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | NAMPT 403/4885MEN1 3301/4885CYP1A2 13/4885 |
| US-20160159772-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | NAMPT 403/4885MEN1 3301/4885CYP1A2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.